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I.  General Information 
 
The following reagents were purchased and used as received: NiBr2•diglyme (Aldrich), 
ligand 1 (Aldrich), i-Pr2O (anhydrous; Aldrich), DMA (absolute, over molecular sieves; Aldrich), 
and KOEt (Strem).  The secondary and tertiary alcohols (precursors to the electrophiles) were 
purchased (Aldrich, TCI, or Alfa Aesar) or were prepared according to literature procedures.  
pinB–Bpin (bis(pinacolato)diboron; Frontier Scientific) and hexB–Bhex (bis(hexylene 
glycolato)diboron; Frontier Scientific) were dried under vacuum at r.t. 
Unless otherwise noted, reactions were conducted with stirring in oven-dried glassware 
under an inert atmosphere. 
1H and 13C NMR spectra were collected on a Bruker Avance 400 spectrometer or a Bruker 
Avance 600 spectrometer at r.t.  The carbon directly attached to the boron was not detected in 
the 13C NMR spectra, likely due to quadropolar relaxation.  GC analyses were carried out on an 
Agilent 6890N series system with a DB-1 column (length 30 m, internal diameter 0.25 mm). 
 
 
II.  Preparation of Electrophiles 
 
The following reagents are commercially available: 1-iodo-3-phenylpropane (Aldrich), 1-
bromo-3-phenylpropane (Aldrich), 4-chlorobenzyl chloride (Alfa Aesar), trans,trans-farnesyl 
chloride (Aldrich; distilled under reduced pressure before use), 2-bromoadamantane (Alfa 
Aesar), benzyl 4-bromopiperidine-1-carboxylate (Aldrich), 3-chlorocyclohexene (TCI; distilled 
under reduced pressure before use), (1-chloroethyl)benzene (TCI), 1-iodoadamantane (Aldrich; 
purified by flash chromatography before use), and exo-2-bromonorbornane (Aldrich). 
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The following halides were prepared according to literature procedures: (3-
iodobutyl)benzene,1 cholesteryl iodide,2 (3-bromobutyl)benzene,3 4-bromo-N,N-
diphenylhexanamide,4 (2-bromo-2-methylpropyl)benzene,5 1-bromo-1-methylcyclohexane,6 (3-
bromo-3-methylbutyl)benzene,7 endo-2-bromonorbornane (endo:exo = 96:4),3 and 2-
chlorononane.8 
 
General Procedure A: Bromination of Secondary Alcohols.3  The alcohol (neat or a solution 
in CH2Cl2) was added to a solution of Ph3PBr2 (1.2 equiv) and imidazole (1.2 equiv) in dry 
CH2Cl2 (0.2 M) at 0 °C.  The reaction mixture was allowed to warm to r.t., and it was stirred 
overnight.  Next, the solvent was removed on a rotary evaporator.  The residue was diluted 
with hexanes/Et2O (4:1), and the resulting solution was filtered and concentrated.  The residue 
was purified by flash column chromatography with 100% hexanes or hexanes/Et2O, or it was 
purified by fractional distillation under reduced pressure. 
 
General Procedure B: Iodination of Tertiary Alcohols.  MeSO3H (2.0 equiv) was added 
dropwise to a solution of NaI (2.0 equiv) and the tertiary alcohol in MeCN (0.2 M in the tertiary 
alcohol) at 0 °C.  The reaction mixture was allowed to warm to r.t., and it was stirred for an 
additional 30 min.  Next, the reaction mixture was diluted with Et2O, washed (water, saturated 
NaHCO3, saturated Na2S2O3, and brine), dried over Na2SO4, and concentrated on a rotary 
evaporator.  The residue was purified by fractional distillation under reduced pressure. 
 
General Procedure C: Bromination of Tertiary Alcohols.  The alcohol (neat or a solution in 
a minimal amount of CH2Cl2) was added to a solution of LiBr (2.0 equiv) in 48 wt% aqueous 
HBr at 0 °C.  The reaction mixture was allowed to warm to r.t., and it was stirred for 3–12 h.  
Next, the reaction mixture was diluted with Et2O, washed (water, saturated NaHCO3, and 
brine), dried over Na2SO4, and concentrated on a rotary evaporator.  The residue was purified 
by fractional distillation under reduced pressure. 
 
General Procedure D: Bromination of Tertiary Alcohols.  PBr3 (0.42 equiv) was added 
dropwise to a solution of the tertiary alcohol and pyridine (0.42 equiv) in anhydrous hexanes 
(0.5 M in alcohol) at 0 °C.  After stirring at 0 °C for 2 h, the reaction mixture was allowed to 
warm to r.t., and it was stirred for an additional 3 h.  Next, the reaction mixture was diluted 
with Et2O, washed (water, saturated NaHCO3, and brine), dried over Na2SO4, and concentrated 
on a rotary evaporator.  The residue was purified by fractional distillation under reduced 
pressure. 
 
                                                
(1) Smith, S.; Fu, G. C. Angew. Chem., Int. Ed. 2008, 47, 9334–9336. 
(2) Powell, D. A.; Maki, T.; Fu, G. C. J. Am. Chem. Soc. 2005, 127, 510–511. 
(3) González-Bobes, F.; Fu, G. C. J. Am. Chem. Soc. 2006, 128, 5360–5361. 
(4) Zultanski, S. L.; Fu, G. C. J. Am. Chem. Soc. 2011, 133, 15362–15364. 
(5) Whitesides, G. M.; Panek, E. J.; Stedronsky, E. R. J. Am. Chem. Soc. 1972, 94, 232–239. 
(6) Cole, S. J.; Kirwan, J. N.; Roberts, B. P.; Willis, C. R. J. Chem. Soc., Perkin Trans. 1 1991, 103–
112. 
(7) Someya, H.; Yorimitsu, H.; Oshima, K. Tetrahedron 2010, 66, 5993–5999. 
(8) Schlenk, W., Jr. Liebigs Ann. Chem. 1973, 1156–1178. 
  S–3 
General Procedure E: Iodination of Secondary Alcohols.9  Iodine chips (1.2 equiv) were 
added to a solution of Ph3P (1.2 equiv) and imidazole (1.2 equiv) in dry CH2Cl2 (0.2 M) at 0 °C.  
The alcohol (neat or a solution in CH2Cl2) was added dropwise to the reaction mixture at 0 °C.  
The mixture was allowed to warm to r.t. and stirred overnight.  Next, the solvent was removed 
on a rotary evaporator.  The residue was diluted with hexanes/Et2O (4:1), filtered, concentrated, 
and purified by flash column chromatography with hexanes. 
 
The yields have not been optimized. 
 
Ph
Br
Me
Me  
 (3-Bromo-4-methylpentyl)benzene [1341946-03-9].  The bromide was prepared according to 
General Procedure A, using 4-methyl-1-phenylpentan-3-ol.10  The product was distilled at 55 °C 
at 0.2 Torr.  Colorless liquid (1.67 g, 36%). 
1H NMR (400 MHz; CDCl3): δ 7.29-7.25 (m, 2H), 7.20-7.16 (m, 3H), 3.95 (dt, J = 10.1, 3.6 Hz, 
1H), 2.96-2.89 (m, 1H), 2.69 (ddd, J = 13.7, 9.1, 7.3 Hz, 1H), 2.18-2.08 (m, 1H), 2.01 (dddd, J = 14.6, 
9.2, 7.2, 3.5 Hz, 1H), 1.83 (d of septets, J = 6.6, 3.7 Hz, 1H), 0.99 (d, J = 6.7 Hz, 3H), 0.95 (d, J = 6.6 
Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 141.3, 128.74, 128.66, 126.3, 66.2, 38.5, 34.9, 34.4, 21.1, 18.3. 
FT-IR (film) 3086, 3063, 3027, 2965, 2874, 1945, 1872, 1804, 1604, 1585, 1496, 1454, 1387, 1368, 
1323, 1239, 1218, 1194, 1158, 1122, 1074, 1030, 973, 924, 906, 852, 793, 749, 699, 657, 618, 580, 517 
cm-1. 
MS (EI) m/z (M+) calcd for C12H1779Br: 240, found: 240, 242 (M++2). 
 
 
Me
Br
Et  
 (Z)-10-Bromoundec-3-ene.  cis-7-Decenal (5.00 mL, 27.3 mmol) was added dropwise to a 
solution of MeMgBr (3.01 M in Et2O; 10.0 mL, 30.0 mmol) at 0 °C.  The resulting solution was 
stirred at 0 °C for 2 h, and then the ice bath was removed and the mixture was stirred for 1 h.  
Next, the reaction was quenched by the addition of saturated aqueous NH4Cl (80 mL), and the 
resulting mixture was extracted with Et2O (2 x 150 mL).  The combined organic layers were 
washed with brine (80 mL), dried over Na2SO4, and concentrated under reduced pressure.  The 
residue was used in the next step without purification.  
The bromide was prepared according to General Procedure A, using the unpurified (Z)-
undec-8-en-2-ol.  The desired product was purified by flash chromatography with hexanes.  
Colorless liquid (2.96 g, 91%). 
                                                
(9) Zhou, J.; Fu, G. C. J. Am. Chem. Soc. 2003, 125, 14726–14727. 
(10) Stymiest, J. L.; Dutheuil, G.; Mahmood, A.; Aggarwal, V. Angew. Chem., Int. Ed. 2007, 46, 
7491–7494. 
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1H NMR (400 MHz; CDCl3): δ 5.37-5.25 (m, 2H), 4.10 (dqd, J = 8.1, 6.6, 5.2 Hz, 1H), 2.04-1.97 
(m, 4H), 1.85-1.70 (m, 2H), 1.67 (d, J = 6.6 Hz, 3H), 1.52-1.43 (m, 1H), 1.42-1.22 (m, 5H), 0.93 (t, J = 
7.5 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 131.9, 129.2, 52.1, 41.3, 29.7, 28.8, 27.8, 27.2, 26.7, 20.7, 14.6. 
FT-IR (film) 3005, 2964, 2931, 2857, 1457, 1404, 1378, 1304, 1243, 1215, 1161, 1069, 996, 885, 
793, 727, 619, 540 cm-1. 
MS (EI) m/z (M+) calcd for C11H2179Br: 232, found: 232, 234 (M++2). 
 
 
N Me
Br
Me
Ph  
N-(3-Bromobutyl)-N-methylaniline.  The bromide was prepared according to General 
Procedure A, using 4-(methyl(phenyl)amino)butan-2-ol.11  The product was purified by flash 
chromatography with hexanes/CH2Cl2 (10:1 → 5:1).  Colorless oil (2.2 g, 53%). 
1H NMR (400 MHz; CDCl3): δ 7.27-7.22 (m, 2H), 6.75-6.69 (m, 3H), 4.20-4.11 (m, 1H), 3.59 
(ddd, J = 14.8, 8.5, 4.6 Hz, 1H), 3.46 (ddd, J = 14.9, 8.2, 6.8 Hz, 1H), 2.96 (s, 3H), 2.13-1.95 (m, 2H), 
1.75 (d, J = 6.7 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 148.2, 132.1, 114.1, 108.5, 51.4, 49.2, 38.9, 37.9, 27.1. 
FT-IR (film) 3093, 3062, 3026, 2966, 2920, 2822, 1918, 1816, 1600, 1574, 1506, 1467, 1450, 1370, 
1345, 1293, 1243, 1215, 1193, 1136, 1119, 1100, 1035, 1009, 991, 969, 943, 908, 863, 811, 749, 693, 
619, 530 cm-1. 
MS (EI) m/z (M+) calcd for C11H1679BrN: 241, found: 241, 243 (M++2). 
 
 
S Et
Br
Me2N
O O  
3-Bromo-N,N-dimethylpentane-1-sulfonamide.  The bromide was prepared according to 
General Procedure A, using 3-hydroxy-N,N-dimethylpentane-1-sulfonamide.12  The product 
was purified by flash chromatography with hexanes/Et2O (2:1 → 1:1).  Colorless oil (2.16 g, 
82%). 
1H NMR (400 MHz; CDCl3): δ 4.07-4.00 (m, 1H), 3.23-3.16 (m, 1H), 3.06-2.99 (m, 1H), 2.87 (s, 
6H), 2.39-2.30 (m, 1H), 2.30-2.14 (m, 1H), 1.91-1.83 (m, 2H), 1.04 (t, 3H, J = 7.2 Hz). 
13C NMR (101 MHz; CDCl3): δ 57.3, 46.5, 37.5, 32.3, 32.1, 12.0. 
FT-IR (film) 2969, 1459, 1333, 1143, 959, 748, 709 cm–1. 
MS (ESI) m/z [M+Na]+ calcd for C7H16BrNNaO2S: 281.9961, found: 281.9967. 
 
                                                
(11) Ibrahim, M. R.; Al-Awadi, N. A.; Ibrahim, Y. A.; Patel, M.; Al-Awadi, S. Tetrahedron 2007, 
63, 4768–4772. 
(12) Synthesized according to: Nwaukwa, S. O.; Lee, S.; Keehn, P. M. Synth. Commun. 1986, 16, 
309–329. 
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Ph I
Me Me
 
 (3-Iodo-3-methylbutyl)benzene [183726-98-9].  The iodide was prepared according to 
General Procedure B, using 2-methyl-4-phenylbutan-2-ol.  The product was distilled at 60 °C at 
0.08 Torr.  Pale-orange liquid (3.5 g, 45%). 
1H NMR (400 MHz; CDCl3): δ 7.31-7.27 (m, 2H), 7.23-7.17 (m, 3H), 2.86-2.82 (m, 2H), 1.99 (s, 
6H), 1.93-1.89 (m, 2H). 
13C NMR (101 MHz; CDCl3): δ 141.6, 128.70, 128.69, 126.2, 52.6, 51.6, 38.3, 35.4. 
 
 
Br
MePh
 
 ((1s,4s)-4-Bromo-4-methylcyclohexyl)benzene (cis).  The bromide was prepared according 
to General Procedure C, using 1-methyl-4-phenylcyclohexanol (trans:cis = 45:55).13  The product 
was purified by recrystallization from hexanes.  White solid (5.25 g, 98%).  Diastereomer ratio: 
>20:1.14 
1H NMR (400 MHz; CDCl3): δ 7.32-7.24 (m, 4H), 7.21-7.17 (m, 1H), 2.47 (tt, J = 12.4, 3.7 Hz, 
1Hd), 2.24-2.18 (m, 2H, He), 2.09-1.99 (m, 2H, Hf), 1.89 (s, 3H), 1.83-1.77 (m, 2H, Hh), 1.55 (ddd, J = 
14.6, 12.6, 3.8 Hz, 2H, Hi). 
13C NMR (101 MHz; CDCl3): δ 146.7, 128.4, 127.0, 126.2, 70.8, 43.5, 43.1, 36.0, 30.9. 
NOE (600 MHz, CDCl3): Irradiation at s 1.89 (Me): 1.2% enhancement at He (2.3% for 2H), 
1.4% enhancement at Hi (2.8% for 2H). 
Me
BrPh
Hd
Hh Hi
Hf He
1.4%
1.2%
0%
 
FT-IR (film) 3081, 3057, 3028, 2974, 2941, 2917, 2864, 2834, 1600, 1493, 1444, 1435, 1378, 1327, 
1301, 1282, 1229, 1198, 1182, 1129, 1115, 1021, 1006, 965, 921, 900, 881, 816, 757, 701, 534, 494 cm-1. 
MS (EI) m/z (M+) calcd for C13H1779Br: 252, found: 252, 254 (M++2). 
 
 
                                                
(13) Wu, Y.-D.; Houk, K. N. J. Am. Chem. Soc. 1987, 109, 908–910. 
(14) For the preparation of the related compound in which there is a t-Bu substituent in place of 
the Ph substituent, see: (a) Damm, W.; Giese, B.; Hartung, J.; Hasskerl, T.; Houk, K. N.; 
Hüter, O.; Zipse, H. J. Am. Chem. Soc. 1992, 114, 4067–4079.  (b) Pasto, D. J.; Gontarz, J. A. J. 
Am. Chem. Soc. 1971, 93, 6902–6908. 
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O Br
Me
 
4-Bromo-4-methyltetrahydro-2H-pyran [66299-88-5].  The bromide was prepared according 
to General Procedure C, using 4-methyltetrahydro-2H-pyran-4-ol.15  The product was distilled 
at 36 °C at 6 Torr.  Colorless liquid (2.74 g, 71%). 
1H NMR (400 MHz; CDCl3): δ 3.84-3.74 (m, 4H), 1.97-1.91 (m, 2H), 1.84 (s, 3H), 1.75-1.68 (m, 
2H). 
13C NMR (101 MHz; CDCl3): δ 66.7, 64.9, 42.3, 35.4. 
 
 
EtO2C Br
Me Me
 
Ethyl 4-bromo-4-methylpentanoate [343863-66-1].  The bromide was prepared according to 
General Procedure D, in the absence of pyridine, using ethyl 4-hydroxy-4-methylpentanoate.16  
The product was distilled at 35 °C at 0.25 Torr.  Colorless liquid (0.58 g, 16%).  The bromide 
should be used in the borylation reaction immediately after the distillation. 
1H NMR (400 MHz; CDCl3): δ 4.11 (q, J = 7.1 Hz, 2H), 2.57-2.53 (m, 2H), 2.10-2.06 (m, 2H), 
1.73 (s, 6H), 1.23 (t, J = 7.1 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 173.3, 66.4, 60.8, 42.0, 34.4, 31.9, 14.4. 
 
 
Br
Me Me
Cl  
5-Bromo-1-chloro-5-methylhexane.  The bromide was prepared according to General 
Procedure D, using 6-chloro-2-methylhexan-2-ol.17  The product was distilled at 34 °C at 0.3 
Torr.  Colorless liquid (4.86 g, 62%).   
1H NMR (400 MHz; CDCl3): δ 3.59 (t, J = 6.6 Hz, 2H), 1.87-1.80 (m, 4H), 1.79 (s, 6H), 1.74-1.66 
(m, 2H). 
13C NMR (101 MHz; CDCl3): δ 67.7, 46.7, 44.8, 34.2, 32.5, 23.8. 
FT-IR (film) 2986, 2956, 2870, 2840, 1453, 1387, 1370, 1309, 1288, 1264, 1231, 1209, 1146, 1106, 
1068, 1008, 987, 933, 885, 812, 742, 653, 601, 526, 499 cm-1. 
MS (EI) m/z (M+) calcd for C7H1479BrCl: 212, found: 161 (M+–CH3–HCl), 163 (M++2–CH3–
HCl). 
 
 
                                                
(15) Booth, H.; Khedhair, K. A.; Readshaw, S. A. Tetrahedron 1987, 43, 4699–4723. 
(16) Reetz, M. T.; Steinbach, R.; Westermann, J.; Peter, R. Angew. Chem., Int. Ed. 1980, 19, 1011–
1012. 
(17) Gebert, U.; Okyayuz-Baklouti, I.; Thorwart, W. Tertiary Hydroxyalkylxanthines, 
Medicaments Containing Them and Their Use. U.S. Patent 4,833,146, May 23, 1989. 
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6-Bromo-2,6-dimethylhept-2-ene [855900-58-2].  The bromide was prepared according to 
General Procedure D, using 2,6-dimethylhept-5-en-2-ol.18  The product was distilled at 31 °C at 
0.3 Torr.  Colorless liquid (4.65 g, 62%). 
1H NMR (400 MHz; CDCl3): δ 5.12 (tdt, J = 7.2, 2.8, 1.4 Hz, 1H), 2.23-2.17 (m, 2H), 1.82-1.78 
(m, 2H), 1.77 (s, 6H), 1.69 (d, J = 1.1 Hz, 3H), 1.63 (d, J = 0.6 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 132.3, 123.3, 68.2, 47.5, 34.2, 25.7, 25.2, 17.7. 
 
 
Me I
Me
( )10  
2-Iodotridecane [64275-39-4].  The iodide was prepared according to General Procedure E, 
using 2-tridecanol.  The product was purified by flash chromatography with hexanes.  Colorless 
liquid (3.27 g, 85%). 
1H NMR (400 MHz; CDCl3): δ 4.16 (dqd, J = 8.4, 6.8, 5.2 Hz, 1H), 1.89 (d, J = 6.8 Hz, 3H), 1.81 
(dddd, J = 14.2, 9.7, 8.6, 4.6 Hz, 1H), 1.62-1.53 (m, 1H), 1.50-1.39 (m, 1H), 1.37-1.23 (m, 17H), 0.85 
(t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 43.2, 32.1, 31.1, 29.9, 29.83, 29.78, 29.7, 29.6, 29.1, 29.0, 22.9, 
14.3. 
 
 
Me Br
Me
( )8  
2-Bromoundecane [39563-54-7].  The bromide was prepared according to General Procedure 
A, using 2-undecanol.  The product was purified by flash chromatography with hexanes.  
Colorless liquid (3.89 g, 86%). 
1H NMR (400 MHz; CDCl3): δ 4.10 (dqd, J = 8.0, 6.6, 5.3 Hz, 1H), 1.85-1.69 (m, 2H), 1.67 (d, J = 
6.7 Hz, 3H), 1.52-1.42 (m, 1H), 1.41-1.34 (m, 1H), 1.29-1.24 (m, 12H), 0.87-0.83 (m, 3H). 
13C NMR (101 MHz; CDCl3): δ 52.2, 41.4, 32.1, 29.73, 29.69, 29.5, 29.2, 28.0, 26.7, 22.9, 14.3. 
 
 
III.  Nickel-Catalyzed Borylations of Primary and Secondary Alkyl Halides 
 
General Procedure: KOEt (77 mg, 0.91 mmol, 1.3 equiv), pinB–Bpin (249 mg, 0.98 mmol, 1.4 
equiv), and i-Pr2O (3.5 mL) were added to a 4-mL vial in a nitrogen-filled glovebox (for a 
glovebox-free procedure, see Section IV).  The vial was sealed with a teflon-lined septum cap, 
and the mixture was stirred vigorously at r.t. for 1 h.  The following materials were added in 
turn to a second 4-mL vial: NiBr2•diglyme (12.3 mg, 0.035 mmol, 0.050 equiv), ligand 1 (13.9 mg, 
                                                
(18) Shenoy, S. R.; Crisóstomo, F. R. P.; Iwasawa, T.; Rebek, J., Jr. J. Am. Chem. Soc. 2008, 130, 
5658–5659. 
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0.046 mmol, 0.066 equiv), and DMA (1.0 mL).  The vial was sealed with a teflon-lined septum 
cap, and the mixture was stirred vigorously at r.t. for 1–2 h (or until the solution became almost 
or completely homogeneous).  This solution was then transferred by syringe to a 20-mL vial, 
and i-Pr2O (4.0 mL) was added.  After stirring for 5 min, the electrophile (0.70 mmol) was 
added.  Next, the white slurry of the activated diboron reagent was added within a 1-min 
period, followed by an i-Pr2O rinsing (0.5 mL).  The vial was sealed with a teflon-lined septum 
cap, and the mixture was stirred at r.t. for 1–7 h, until judged complete by GC analysis.  Then, it 
was filtered through a short pad of silica gel, eluting with Et2O (25 mL).  The solvents were 
removed in vacuo, and the residue was purified by flash chromatography (if the products are 
exposed to silica gel for an extended period of time or left unpurified for >12 h, a lower yield is 
observed). 
 
 
Ph B
O
O
Me
Me
Me
Me  
4,4,5,5-Tetramethyl-2-(3-phenylpropyl)-1,3,2-dioxaborolane [329685-40-7]19 (Table 1, Entry 
1).  The title compound was prepared according to the General Procedure, using 1-iodo-3-
phenylpropane (172 mg, 0.70 mmol).  The reaction was complete after 3 h.  Solvent used for 
chromatography: hexanes/Et2O (40:1 → 20:1).  Colorless liquid. 
First run: 123 mg (71%).  Second run: 126 mg (73%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.22 (m, 2H), 7.16-7.12 (m, 3H), 2.59 (t, J = 7.8 Hz, 2H), 
1.75-1.67 (m, 2H), 1.22 (s, 12H), 0.81 (t, J = 7.9 Hz, 2H). 
13C NMR (101 MHz; CDCl3): δ 142.9, 128.8, 128.4, 125.8, 83.1, 38.8, 26.3, 25.0. 
 
 
Ph B
O
O
Me
Me
Me
Me  
4,4,5,5-Tetramethyl-2-(3-phenylpropyl)-1,3,2-dioxaborolane [329685-40-7]19 (Table 1, Entry 
2).  The title compound was prepared according to the General Procedure, using 1-bromo-3-
phenylpropane (139 mg, 0.70 mmol).  The reaction was complete after 3 h.  Solvent used for 
chromatography: hexanes/Et2O (40:1 → 20:1).  Colorless liquid. 
First run: 122 mg (71%).  Second run: 121 mg (70%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.22 (m, 2H), 7.16-7.12 (m, 3H), 2.59 (t, J = 7.8 Hz, 2H), 
1.76-1.68 (m, 2H), 1.22 (s, 12H), 0.81 (t, J = 7.9 Hz, 2H). 
13C NMR (101 MHz; CDCl3): δ 142.9, 128.8, 128.4, 125.8, 83.1, 38.8, 26.3, 25.0. 
 
 
                                                
(19) (a) Yamamoto, Y.; Fujikawa, R.; Umemoto, T.; Miyaura, N. Tetrahedron 2004, 60, 10695–
10700.  (b) Caballero, A.; Sabo-Etienne, S. Organometallics 2007, 26, 1191–1195.  (c) Lata, C. 
J.; Crudden, C. M. J. Am. Chem. Soc. 2010, 132, 131–137. 
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2-(4-Chlorobenzyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [517920-59-1]20 (Table 1, Entry 
3).  The title compound was prepared according to the General Procedure, using 4-chlorobenzyl 
chloride (113 mg, 0.70 mmol).  The reaction was complete after 3 h.  Solvent used for 
chromatography: hexanes/Et2O (20:1).  White solid. 
First run: 109 mg (61%, 75% calibrated GC).  Second run: 106 mg (60%, 75% calibrated GC). 
1H NMR (400 MHz; CDCl3): δ 7.17 (d, J = 8.4 Hz, 2H), 7.09-7.07 (m, 2H), 2.22 (s, 2H), 1.20 (s, 
12H). 
13C NMR (101 MHz; CDCl3): δ 137.3, 130.8, 130.5, 128.5, 83.7, 24.9. 
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Me Me Me
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Me
Me
Me  
4,4,5,5-Tetramethyl-2-((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl)-1,3,2-dioxaborolane 
[1268820-35-4]21 (Table 1, Entry 4).  The title compound was prepared according to the General 
Procedure, using trans,trans-farnesyl chloride (169 mg, 0.70 mmol).  The reaction was complete 
after 4 h.  Solvent used for chromatography: hexanes/Et2O (1:0 → 40:1).  Colorless liquid. 
First run: 155 mg (67%, 79% calibrated GC).  Second run: 154 mg (66%, 78% calibrated GC). 
1H NMR (400 MHz; CDCl3): δ 5.24-5.20 (m, 1H), 5.10-5.03 (m, 2H), 2.06-1.91 (m, 8H), 1.64 (d, J 
= 1.0 Hz, 3H), 1.56 (s, 11H), 1.21 (s, 12H). 
13C NMR (101 MHz; CDCl3): δ 135.4, 134.9, 131.4, 124.62, 124.58, 118.7, 83.2, 39.97, 39.94, 
26.99, 26.97, 25.9, 24.9, 17.9, 16.17, 16.12. 
 
 
                                                
(20) (a) Pintaric, C.; Olivero, S.; Gimbert, Y.; Chavant, P. Y.; Duñach, E. J. Am. Chem. Soc. 2010, 
132, 11825–11827.  (b) Ishiyama, T.; Oohashi, Z.; Ahiko, T.-a.; Miyaura, N. Chem. Lett. 2002, 
780–781.  (c) Li, H.; Wang, L.; Zhang, Y.; Wang, J. Angew. Chem., Int. Ed. 2012, 51, 2943–
2946. 
(21) Fujiwara, Y.; Domingo, V.; Seiple, I. B.; Gianatassio, R.; Del Bel, M.; Baran, P. S. J. Am. 
Chem. Soc. 2011, 133, 3292–3295. 
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4,4,5,5-Tetramethyl-2-(4-phenylbutan-2-yl)-1,3,2-dioxaborolane [1257661-35-0]22 (Table 2, 
Entry 1).  The title compound was prepared according to the General Procedure, using (3-
iodobutyl)benzene (182 mg, 0.70 mmol).  The reaction was complete after 1.5 h.  Solvent used 
for chromatography: hexanes/Et2O (40:1 → 20:1).  Colorless liquid. 
First run: 143 mg (79%).  Second run: 134 mg (74%). 
1H NMR (400 MHz; CDCl3): δ 7.27-7.23 (m, 2H), 7.18-7.12 (m, 3H), 2.66-2.55 (m, 2H), 1.82-1.73 
(m, 1H), 1.62-1.53 (m, 1H), 1.23 (s, 12H), 1.10-1.03 (m, 1H), 1.02-1.00 (m, 3H). 
13C NMR (101 MHz; CDCl3): δ 143.3, 128.6, 128.4, 125.7, 83.1, 35.54, 35.52, 25.02, 24.97, 15.6. 
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H
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3-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)cholest-5-ene (Table 2, Entry 2).  The title 
compound was prepared according to the General Procedure, using cholesteryl iodide (348 mg, 
0.70 mmol).  The reaction was complete after 3 h.  Solvent used for chromatography: 
hexanes/Et2O (40:1).  White solid.  Diastereoselectivity: 3:1 (3β:3α); assigned by comparison of 
the 1H NMR resonances of the 3-hydroxy compound, obtained after oxidation using 
NaBO3/THF/H2O, with literature data.23 
First run: 300 mg (86%).  Second run: 301 mg (86%). 
1H NMR (400 MHz; CDCl3): δ (major+minor) 5.31-5.22 (m, 1H), 2.40-2.12 (m, 1H), 2.02-1.68 
(m, 5H), 1.62-1.23 (m, 12H), 1.20-1.16 (m, 12H), 1.12-0.93 (m, 13H), 0.88 (d, J = 6.6 Hz, 4H), 0.83 
(dd, J = 6.6, 1.8 Hz, 6H), 0.64 (s, 3H). 
13C NMR (101 MHz; CDCl3): δ (major+minor) 144.0, 142.8, 120.0, 118.7, 83.01, 83.00, 57.08, 
57.06, 56.4, 51.4, 50.8, 42.5, 41.1, 40.08, 40.06, 39.7, 39.1, 37.5, 36.4, 36.01, 35.98, 34.4, 34.0, 32.3, 
32.1, 32.04, 32.02, 28.5, 28.2, 25.2, 24.96, 24.94, 24.8, 24.5, 24.3, 24.05, 23.98, 23.7, 23.03, 23.01, 22.8, 
20.99, 20.95, 19.7, 19.6, 18.9, 12.1. 
                                                
(22) (a) Larouche-Gauthier, R.; Fletcher, C. J.; Couto, I.; Aggarwal, V. K. Chem. Commun. 2011, 
47, 12592–12594.  (b) Larouche-Gauthier, R.; Elford, T. G.; Aggarwal, V. K. J. Am. Chem. Soc. 
2011, 133, 16794–16797. 
(23) Lee, E.; Lee, Y. R.; Moon, B.; Kwon, O.; Shim, M. S.; Yun, J. S. J. Org. Chem. 1994, 59, 1444–
1456. 
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FT-IR (film) 2934, 2868, 1467, 1412, 1384, 1313, 1267, 1234, 1214, 1146, 1110, 1026, 970, 909, 
856, 799, 743 cm-1. 
MS (EI) m/z (M+) calcd for C33H57BO2: 496, found: 496. 
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4,4,5,5-Tetramethyl-2-(4-phenylbutan-2-yl)-1,3,2-dioxaborolane [1257661-35-0]22 (Table 2, 
Entry 3).  The title compound was prepared according to the General Procedure, using (3-
bromobutyl)benzene (149 mg, 0.70 mmol).  The reaction was complete after 2 h.  Solvent used 
for chromatography: hexanes/Et2O (40:1 → 20:1).  Colorless liquid. 
First run: 157 mg (86%).  Second run: 159 mg (87%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.21 (m, 2H), 7.18-7.11 (m, 3H), 2.66-2.54 (m, 2H), 1.81-1.72 
(m, 1H), 1.61-1.52 (m, 1H), 1.23 (s, 12H), 1.09-1.02 (m, 1H), 1.00 (d, J = 6.3 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 143.3, 128.6, 128.4, 125.7, 83.1, 35.53, 35.51, 25.01, 24.96, 15.6. 
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4,4,5,5-Tetramethyl-2-(4-methyl-1-phenylpentan-3-yl)-1,3,2-dioxaborolane [1201898-72-7]24 
(Table 2, Entry 4).  The title compound was prepared according to the General Procedure, using 
(3-bromo-4-methylpentyl)benzene (169 mg, 0.70 mmol).  The reaction was complete after 4 h.  
Solvent used for chromatography: hexanes/Et2O (40:1 → 30:1).  Colorless liquid. 
First run: 118 mg (58%).  Second run: 121 mg (60%). 
1H NMR (400 MHz; CDCl3): δ 7.27-7.22 (m, 2H), 7.18-7.12 (m, 3H), 2.62 (ddd, J = 13.5, 10.9, 5.2 
Hz, 1H), 2.49 (ddd, J = 13.5, 10.6, 6.3 Hz, 1H), 1.79-1.60 (m, 3H), 1.26 (s, 12H), 0.93-0.87 (m, 7H). 
13C NMR (101 MHz; CDCl3): δ 143.4, 128.6, 128.4, 125.7, 83.1, 36.2, 31.6, 29.8, 25.3, 25.1, 22.5, 
21.9. 
 
 
                                                
(24) Bagutski, V.; Ros, A.; Aggarwal, V. K. Tetrahedron 2009, 65, 9956–9960. 
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2-Adamantan-2-yl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 2, Entry 5).  The title 
compound was prepared according to the General Procedure, using 2-bromoadamantane (151 
mg, 0.70 mmol).  The reaction was complete after 7 h.  Solvent used for chromatography: 
hexanes/Et2O (40:1).  White solid. 
First run: 120 mg (65%, 70% calibrated GC).  Second run: 121 mg (66%, 69% calibrated GC). 
1H NMR (400 MHz; CDCl3): δ 2.02 (br d, J = 1.2 Hz, 2H), 1.85-1.64 (m, 12H), 1.33 (br s, 1H), 
1.22 (s, 12H). 
13C NMR (101 MHz; CDCl3): δ 82.9, 39.5, 37.9, 36.5, 29.5, 28.4, 28.3, 25.0. 
FT-IR (film) 2977, 2902, 2846, 2648, 1450, 1407, 1380, 1364, 1351, 1306, 1287, 1272, 1214, 1166, 
1145, 1111, 1098, 1057, 1044, 980, 963, 876, 850, 806, 739, 669, 639, 556 cm-1. 
MS (EI) m/z (M+) calcd for C16H27BO2: 262, found: 262. 
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Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)piperidine-1-carboxylate (Table 2, 
Entry 6).  The title compound was prepared according to the General Procedure, using benzyl 4-
bromopiperidine-1-carboxylate (209 mg, 0.70 mmol).  The reaction was complete after 6 h.  
Solvent used for chromatography: hexanes/Et2O (5:1 → 3:1).  The product was washed with a 1 
M solution of Na2CO3 to remove traces of excess pinB–Bpin.  White solid. 
First run: 187 mg (77%).  Second run: 199 mg (82%). 
1H NMR (400 MHz; CDCl3): δ 7.35-7.30 (m, 4H), 7.30-7.24 (m, 1H), 5.08 (s, 2H), 3.85-3.79 (m, 
2H), 3.01-2.96 (m, 2H), 1.64-1.55 (m, 2H), 1.55-1.42 (m, 2H), 1.20 (s, 12H), 1.10 (tt, J = 10.4, 3.9 Hz, 
1H). 
13C NMR (101 MHz; CDCl3): δ 155.5, 137.3, 128.6, 128.02, 127.96, 83.4, 67.0, 45.3, 27.1 (broad, 
low intensity), 25.0. 
FT-IR (film) 2978, 2935, 2853, 1701, 1498, 1469, 1431, 1381, 1335, 1276, 1263, 1241, 1180, 1145, 
1101, 1067, 1022, 968, 950, 912, 852, 764, 738, 698, 670, 603, 554 cm-1. 
MS (EI) m/z (M+) calcd for C19H28BNO4: 345, found: 345. 
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 (Z)-4,4,5,5-Tetramethyl-2-(undec-8-en-2-yl)-1,3,2-dioxaborolane (Table 2, Entry 7).  The 
title compound was prepared according to the General Procedure, using (Z)-10-bromoundec-3-
ene (97:3 Z:E) (163 mg, 0.70 mmol).  The reaction was complete after 2.5 h.  Solvent used for 
chromatography: hexanes/Et2O (40:1).  Colorless liquid.  95:5 Z:E. 
First run: 166 mg (85%).  Second run: 164 mg (83%). 
1H NMR (400 MHz; CDCl3): δ 5.34-5.25 (m, 2H), 2.03-1.92 (m, 4H), 1.44-1.36 (m, 1H), 1.31-1.23 
(m, 7H), 1.20 (s, 12H), 0.99-0.89 (m, 7H). 
13C NMR (101 MHz; CDCl3): δ 131.6, 129.6, 82.9, 33.4, 30.0, 29.7, 29.0, 27.3, 24.94, 24.91, 20.7, 
15.7, 14.6. 
FT-IR (film) 2977, 2927, 2855, 1654, 1464, 1405, 1387, 1371, 1315, 1274, 1239, 1215, 1146, 1112, 
1069, 1005, 968, 861, 794, 688, 670, 579, 521 cm-1. 
MS (EI) m/z (M+) calcd for C17H33BO2: 280, found: 280. 
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N-Methyl-N-(3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)butyl)aniline (Table 2, Entry 
8).  The title compound was prepared according to the General Procedure, using N-(3-
bromobutyl)-N-methylaniline (170 mg, 0.70 mmol).  The reaction was complete after 4 h.  
Solvent used for chromatography: hexanes/Et2O (20:1 → 10:1).  Colorless oil. 
First run: 140 mg (69%).  Second run: 138 mg (68%). 
1H NMR (400 MHz; CDCl3): δ 7.22-7.16 (m, 2H), 6.72 (dt, J = 9.0, 1.6 Hz, 2H), 6.64 (tt, J = 7.2, 
0.9 Hz, 1H), 3.36-3.23 (m, 2H), 2.89 (s, 3H), 1.74-1.66 (m, 1H), 1.58-1.50 (m, 1H), 1.23 (s, 12H), 
1.04-0.97 (m, 4H). 
13C NMR (101 MHz; CDCl3): δ 149.6, 129.2, 115.9, 112.3, 83.2, 52.6, 38.3, 30.0, 25.05, 24.99, 15.9. 
FT-IR (film) 3094, 3061, 3026, 2977, 2871, 1600, 1575, 1508, 1464, 1371, 1319, 1235, 1215, 1144, 
1113, 1035, 990, 967, 862, 837, 747, 692, 671, 579, 517 cm-1. 
MS (EI) m/z (M+) calcd for C17H28BNO2: 289, found: 289. 
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N,N-Diphenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)hexanamide (Table 2, Entry 
9).  The title compound was prepared according to the General Procedure, using 4-bromo-N,N-
diphenylhexanamide (242 mg, 0.70 mmol).  The reaction was complete after 3 h.  Solvent used 
for the first chromatography: hexanes/Et2O (2:1); solvent used for the second chromatography: 
CH2Cl2/Et2O (15:1).  White solid. 
First run: 173 mg (63%).  Second run: 177 mg (64%). 
1H NMR (400 MHz; CDCl3): δ 7.47-7.08 (br m, 10H), 2.37-2.20 (m, 2H), 1.86-1.69 (m, 2H), 1.45-
1.29 (m, 2H), 1.14 (d, J = 2.4 Hz, 12H), 0.90-0.82 (m, 4H). 
13C NMR (101 MHz; CDCl3): δ 173.5, 143.3, 126.6-129.3 (br; two resonances), 83.1, 35.3, 27.1, 
24.99, 24.94, 24.4, 13.7. 
FT-IR (film) 3063, 2976, 2930, 2871, 1676, 1594, 1493, 1453, 1372, 1315, 1269, 1215, 1144, 1111, 
1075, 1031, 1005, 966, 901, 855, 757, 702, 622, 579, 521 cm-1. 
MS (EI) m/z (M+) calcd for C24H32BNO3: 393, found: 393. 
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N,N-Dimethyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentane-1-sulfonamide 
(Table 2, Entry 10).  The title compound was prepared according to the General Procedure, 
using 3-bromo-N,N-dimethylpentane-1-sulfonamide (181 mg, 0.70 mmol).  The reaction was 
complete after 3 h.  Solvent used for the first chromatography: hexanes/Et2O (2:1); solvent used 
for the second chromatography: CH2Cl2/Et2O (100:0 → 15:1).  Colorless oil. 
First run: 149 mg (70%).  Second run: 148 mg (69%). 
1H NMR (400 MHz; CDCl3): δ 3.03-2.87 (m, 2H), 2.84 (s, 6H), 1.88-1.74 (m, 2H), 1.41 (m, 2H), 
1.20 (s, 12H), 0.95 (ddd, J = 14.1, 7.8, 5.9 Hz, 1H), 0.88 (t, J = 7.4 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 83.5, 48.3, 37.7, 25.06, 24.96, 24.2, 23.9, 13.4. 
FT-IR (film) 2976, 2945, 2875, 1462, 1389, 1335, 1270, 1214, 1145, 1057, 963, 894, 854, 793, 747, 
709, 670, 558, 498, 484 cm-1. 
MS (EI) m/z (M+) calcd for C13H28BNO4S: 305, found: 305. 
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2-(Cyclohex-2-enyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [167773-14-0]25 (Table 2, Entry 
11).  The title compound was prepared according to the General Procedure, using 3-
chlorocyclohexene (82 mg, 0.70 mmol).  The reaction was complete after 4 h.  Due to the 
volatility of the product, the DMA was not evaporated from the crude reaction mixture.  Solvent 
used for chromatography: hexanes/Et2O (1:0 → 40:1).  Colorless liquid. 
First run: 86 mg (59%).  Second run: 89 mg (61%). 
1H NMR (400 MHz; CDCl3): δ 5.71-5.60 (m, 2H), 2.07-1.93 (m, 2H), 1.77-1.52 (m, 5H), 1.21 (s, 
12H). 
13C NMR (101 MHz; CDCl3): δ 127.8, 126.2, 83.3, 25.2, 25.0, 24.8, 24.3, 22.7. 
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4,4,5,5-Tetramethyl-2-(1-phenylethyl)-1,3,2-dioxaborolane [174090-36-9]20a,26 (Table 2, Entry 
12).  The title compound was prepared according to the General Procedure for tertiary alkyl 
halides (see below), using (1-chloroethyl)benzene (98 mg, 0.70 mmol).  The reaction was 
complete after 3 h.  Solvent used for chromatography: hexanes/Et2O (40:1 → 20:1).  Colorless 
liquid. 
First run: 120 mg (74%).  Second run: 118 mg (73%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.19 (m, 4H), 7.11 (tt, J = 7.0, 1.7 Hz, 1H), 2.42 (q, J = 7.5 
Hz, 1H), 1.31 (d, J = 7.5 Hz, 3H), 1.19 (s, 6H), 1.18 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 145.2, 128.5, 128.0, 125.3, 83.5, 24.83, 24.79, 17.3. 
 
 
IV.  Nickel-Catalyzed Borylations of Tertiary Alkyl Halides 
 
General Procedure: KOEt (82 mg, 0.98 mmol, 1.4 equiv), pinB–Bpin (267 mg, 1.05 mmol, 1.5 
equiv), and i-Pr2O (3.5 mL) were added to a 4-mL vial in a nitrogen-filled glovebox (for a 
                                                
(25) (a) Yang, C.-T.; Zhang, Z.-Q.; Tajuddin, H.; Wu, C.-C.; Liang, J.; Liu, J.-H.; Fu, Y.; 
Czyzewska, M.; Steel, P. G.; Marder, T. B.; Liu, L. Angew. Chem., Int. Ed. 2012, 51, 528–532.  
(b) Wu, J. Y.; Moreau, B.; Ritter, T. J. Am. Chem. Soc. 2009, 131, 12915–12917.  (c) Dutheuil, 
G.; Selander, N.; Szabó, K. J.; Aggarwal, V. K. Synthesis 2008, 2293–2297.  (d) Ito, H.; 
Kawakami, C.; Sawamura, M. J. Am. Chem. Soc. 2005, 127, 16034–16035.  (e) Ely, R. J.; 
Morken, J. P. J. Am. Chem. Soc. 2010, 132, 2534–2535. 
(26) Noh, D.; Chea, H.; Ju, J.; Yun, J. Angew. Chem., Int. Ed. 2009, 48, 6062–6064. 
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glovebox-free procedure, see below).  The vial was sealed with a teflon-lined septum cap, and 
the mixture was stirred vigorously at r.t. for 1 h.  The following materials were added in turn to 
a second 4-mL vial: NiBr2•diglyme (24.7 mg, 0.070 mmol, 0.10 equiv), ligand 1 (27.4 mg, 0.091 
mmol, 0.13 equiv), and DMA (1.0 mL).  The vial was sealed with a teflon-lined septum cap, and 
the mixture was stirred vigorously at r.t. for 1–2 h (or until the solution became almost or 
completely homogeneous).  This solution was then transferred by syringe to a 20-mL vial, and i-
Pr2O (12.0 mL) was added.  After stirring for 5 min, the electrophile (0.70 mmol) was added.  
Next, the white slurry of the activated diboron reagent was added within a 1-min period, 
followed by an i-Pr2O rinsing (1.0 mL).  The vial was sealed with a teflon-lined septum cap, and 
the mixture was stirred at r.t. for 1–6 h, until judged complete by GC analysis.  Then, it was 
filtered through a short pad of silica gel, eluting with Et2O (25 mL).  The solvents were removed 
in vacuo, and the residue was purified by flash chromatography (if the products are exposed to 
silica gel for an extended period of time or left unpurified for >12 h, a lower yield is observed). 
 
Glovebox-free procedure A (using KOEt): All glassware was dried in a vacuum oven and 
then cooled to r.t. under an atmosphere of nitrogen.  Under a flow of argon, pinB–Bpin (267 mg, 
1.05 mmol, 1.5 equiv) and KOEt (82 mg, 0.98 mmol, 1.4 equiv) were added quickly to a 4-mL 
vial, and the vial was sealed with a teflon-lined septum cap.  The vial was evacuated and 
backfilled with nitrogen three times, and then i-Pr2O (3.5 mL) was added via syringe.  The 
resulting mixture was stirred vigorously at r.t. for 1 h under an atmosphere of nitrogen.  In the 
air, the following materials were added in turn to a second 4-mL vial: NiBr2•diglyme (24.7 mg, 
0.070 mmol, 0.10 equiv) and ligand 1 (27.4 mg, 0.091 mmol, 0.13 equiv).  The vial was sealed 
with a teflon-lined septum cap, and then the vial was evacuated and backfilled with nitrogen 
three times.  Next, DMA (1.0 mL) was added via syringe.  The resulting mixture was stirred 
vigorously at r.t. for 1–2 h (or until the solution became almost or completely homogeneous).  A 
20-mL vial, sealed with a teflon-lined septum cap, was evacuated and backfilled with nitrogen 
three times, and then i-Pr2O (12.0 mL) was added via syringe.  The solution of nickel/ligand in 
DMA was transferred by syringe to the 20-mL vial.  The solution was stirred for 5 min, and then 
the electrophile (0.70 mmol) was added.  Next, the white slurry of the activated diboron reagent 
was added via syringe within a 1-min period to the 20-mL vial, followed by an i-Pr2O rinsing 
(1.0 mL).  The reaction mixture was stirred at r.t. for 1–6 h under an atmosphere of nitrogen, 
until judged complete by GC analysis.  Then, it was filtered through a short pad of silica gel, 
eluting with Et2O (25 mL).  The solvents were removed in vacuo, and the residue was purified 
by flash chromatography (if the products are exposed to silica gel for an extended period of 
time or left unpurified for >12 h, a lower yield is observed). 
When employed for the borylation illustrated in Entry 6 of Table 3 (reaction time: 2 h), the 
desired product was isolated in 72% yield (130 mg). 
 
Glovebox-free procedure B (using KOt-Bu and EtOH): All glassware was dried in a 
vacuum oven and then cooled to r.t. under an atmosphere of nitrogen.  In the air, pinB–Bpin 
(267 mg, 1.05 mmol, 1.5 equiv) was added to a 4-mL vial, and the vial was sealed with a teflon-
lined septum cap.  The vial was evacuated and backfilled with nitrogen three times, and then i-
Pr2O (2.5 mL) was added via syringe.  In the air, KOt-Bu (110 mg, 0.98 mmol, 1.4 equiv) was 
added to a second 4-mL vial, and the vial was sealed with a teflon-lined septum cap.  The vial 
was evacuated and backfilled with nitrogen three times, and then i-Pr2O (1.0 mL) and 
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anhydrous EtOH (57 µL, 0.98 mmol, 1.4 equiv) were added via syringe.  The resulting mixture 
was stirred vigorously at r.t. for 20 min under an atmosphere of nitrogen, and then the solution 
of pinB–Bpin was added via cannula.  The resulting mixture was stirred vigorously at r.t. for 1 h 
under an atmosphere of nitrogen.  In the air, the following materials were added in turn to a 
third 4-mL vial: NiBr2•diglyme (24.7 mg, 0.070 mmol, 0.10 equiv) and ligand 1 (27.4 mg, 0.091 
mmol, 0.13 equiv), and the vial was sealed with a teflon-lined septum cap.  The vial was 
evacuated and backfilled with nitrogen three times, and then DMA (1.0 mL) was added via 
syringe.  The resulting mixture was stirred vigorously at r.t. for 1–2 h (or until the solution 
became almost or completely homogeneous).  A 20-mL vial, sealed with a teflon-lined septum 
cap, was evacuated and backfilled with nitrogen three times, and then i-Pr2O (12.0 mL) was 
added via syringe.  The solution of nickel/ligand in DMA was transferred by syringe to the 20-
mL vial.  The mixture was stirred for 5 min, and then the electrophile (0.70 mmol) was added.  
Next, the white slurry of the activated diboron reagent was added via syringe within a 1-min 
period to the 20-mL vial, followed by an i-Pr2O rinsing (1.0 mL).  The reaction mixture was 
stirred at r.t. for 1–6 h under an atmosphere of nitrogen, until judged complete by GC analysis.  
Then, it was filtered through a short pad of silica gel, eluting with Et2O (25 mL).  The solvents 
were removed in vacuo, and the residue was purified by flash chromatography (if the products 
are exposed to silica gel for an extended period of time or left unpurified for >12 h, a lower yield 
is observed). 
When employed for the borylation illustrated in Entry 6 of Table 3 (reaction time: 2 h), the 
desired product was isolated in 74% yield (135 mg). 
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2-Adamantan-1-yl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [1357000-33-9]27 (Table 3, Entry 
1).  The title compound was prepared according to the General Procedure, using 1-
iodoadamantane (184 mg, 0.70 mmol).  The reaction was complete after 3 h.  Solvent used for 
chromatography: hexanes/Et2O (1:0 → 40:1).  White semi-solid. 
First run: 139 mg (75%).  Second run: 132 mg (72%). 
1H NMR (400 MHz; CDCl3): δ 1.81 (br s, 3H), 1.72 (br t, J = 3.1 Hz, 12H), 1.17 (s, 12H). 
13C NMR (101 MHz; CDCl3): δ 82.8, 38.2, 37.7, 27.8, 24.8. 
 
 
                                                
(27) Ito, H.; Kubota, K. Org. Lett. 2012, 14, 890–893. 
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4,4,5,5-Tetramethyl-2-(2-methyl-4-phenylbutan-2-yl)-1,3,2-dioxaborolane (Table 3, Entry 
2).  The title compound was prepared according to the General Procedure, using (3-iodo-3-
methylbutyl)benzene (192 mg, 0.70 mmol).  The reaction was complete after 2 h.  Solvent used 
for chromatography: hexanes/Et2O (1:0 → 40:1).  White/colorless needles. 
First run: 75 mg (39%).  Second run: 79 mg (41%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.22 (m, 2H), 7.18-7.11 (m, 3H), 2.56-2.51 (m, 2H), 1.58-1.54 
(m, 2H), 1.23 (s, 12H), 0.97 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 143.9, 128.5, 128.4, 125.6, 83.2, 43.7, 33.3, 24.98, 24.96. 
FT-IR (film) 3086, 3063, 3027, 2977, 2936, 2862, 1605, 1497, 1475, 1455, 1389, 1371, 1310, 1267, 
1194, 1166, 1137, 1070, 1031, 1005, 966, 855, 767, 746, 717, 699, 671, 580, 521, 498, 467 cm-1. 
MS (EI) m/z (M+) calcd for C17H27BO2: 274, found: 274. 
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4,4,5,5-Tetramethyl-2-(1-methylcyclohexyl)-1,3,2-dioxaborolane [255041-54-4] (Table 3, 
Entry 3).  The title compound was prepared according to the General Procedure, using 1-bromo-
1-methylcyclohexane (124 mg, 0.70 mmol).  The reaction was complete after 3 h.  Due to the 
volatility of the product, the DMA was not evaporated from the crude reaction mixture, but it 
was washed out via extraction with water.  Solvent used for chromatography: hexanes/Et2O 
(1:0 → 40:1).  Colorless liquid. 
First run: 104 mg (66%).  Second run: 106 mg (68%). 
1H NMR (400 MHz; CDCl3): δ 1.81-1.76 (m, 2H), 1.62-1.53 (m, 3H), 1.28-1.15 (m, 14H), 1.15-
1.04 (m, 1H), 0.90-0.83 (m, 5H). 
13C NMR (101 MHz; CDCl3): δ 82.8, 37.0, 26.4, 25.9, 25.5, 24.7. 
FT-IR (film) 2978, 2924, 2854, 2671, 1465, 1388, 1336, 1317, 1303, 1263, 1233, 1215, 1165, 1145, 
1109, 1083, 1042, 1020, 968, 932, 895, 859, 847, 828, 715, 691, 670, 580, 550, 470 cm-1. 
MS (EI) m/z (M+) calcd for C13H25BO2: 224, found: 224. 
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4,4,5,5-Tetramethyl-2-((1s,4s)-1-methyl-4-phenylcyclohexyl)-1,3,2-dioxaborolane (cis) 
(Table 3, Entry 4).  The title compound was prepared according to the General Procedure, using 
((1s,4s)-4-bromo-4-methylcyclohexyl)benzene (cis) (177 mg, 0.70 mmol).  The reaction was 
  S–19 
complete after 3 h.  Solvent used for chromatography: hexanes/Et2O (1:0 → 30:1).  Colorless 
viscous oil.  Diastereoselectivity: 11:1 (cis:trans; not separated). 
First run: 143 mg (68%).  Second run: 153 mg (73%). 
1H NMR (400 MHz; CDCl3): δ (major, cis) 7.29-7.24 (m, 2H), 7.22-7.20 (m, 2H), 7.17-7.13 (m, 
1H), 2.51-2.43 (m, 1H), 1.77-1.60 (m, 6H), 1.57-1.51 (m, 2H), 1.23 (s, 12H), 1.06 (s, 3H). 
13C NMR (101 MHz; CDCl3): δ (major, cis) 148.0, 128.3, 126.9, 125.7, 82.8, 44.1, 32.9, 28.0, 24.7, 
18.6. 
1H NMR (600 MHz; (CD3)2CO): δ (major, cis) 7.31-7.27 (m, 4H), 7.17 (tt, J = 6.6, 1.9 Hz, 1H), 
2.50 (tt, J = 11.4, 3.7 Hz, 1H, Hc), 1.78 (qd, J = 12.2, 2.8 Hz, 2H, Hd), 1.70 (td, J = 12.8, 3.1 Hz, 2H, 
He), 1.62-1.59 (m, 2H, Hf), 1.54 (br d, J = 13.2 Hz, 2H, Hg), 1.25 (s, 12H), 1.08 (s, 3H, CH3, Hi). 
13C NMR (151 MHz; (CD3)2CO): δ (major, cis) 148.0, 128.4, 127.0, 125.8, 82.8, 44.3, 33.0, 28.2, 
24.3, 18.5. 
NOE (600 MHz, (CD3)2CO) Irradiation at s 1.08 (CH3, Hi): 0.8% enhancement at Hg (1.5% for 
2H), 1.1% enhancement at Hd (2.1% for 2H). 
CH3iPh
Hc
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Hd Hg
1.1%
0.8%
B O
O
Me
Me
Me
Me
 
FT-IR (film) 3061, 3027, 2977, 2924, 2858, 1602, 1493, 1467, 1400, 1379, 1338, 1308, 1257, 1216, 
1166, 1150, 1131, 1097, 1020, 971, 850, 756, 699, 671, 580, 531 cm-1. 
MS (EI) m/z (M+) calcd for C19H29BO2: 300, found: 300. 
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4,4,5,5-Tetramethyl-2-(4-methyltetrahydro-2H-pyran-4-yl)-1,3,2-dioxaborolane (Table 3, 
Entry 5).  The title compound was prepared according to the General Procedure, using 4-bromo-
4-methyltetrahydro-2H-pyran (125 mg, 0.70 mmol).  The reaction was complete after 4 h.  Due to 
the volatility of the product, the DMA was not evaporated from the crude reaction mixture, but 
it was washed out via extraction with water.  Solvent used for chromatography: hexanes/Et2O 
(10:1 → 7:1).  Colorless liquid. 
First run: 115 mg (72%).  Second run: 113 mg (72%). 
1H NMR (400 MHz; CDCl3): δ 3.85-3.80 (m, 2H), 3.34 (td, J = 11.8, 2.2 Hz, 2H), 1.72 (dq, J = 
13.1, 2.1 Hz, 2H), 1.26-1.15 (m, 14H), 0.92 (s, 3H). 
13C NMR (101 MHz; CDCl3): δ 83.4, 67.6, 36.9, 25.7, 24.9. 
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FT-IR (film) 3051, 2979, 2952, 2838, 2752, 2692, 1460, 1437, 1380, 1323, 1308, 1274, 1247, 1235, 
1214, 1199, 1165, 1143, 1103, 1086, 1034, 1014, 984, 966, 885, 855, 837, 739, 716, 694, 670, 604, 579 
cm-1. 
MS (EI) m/z (M+) calcd for C12H23BO3: 226, found: 226. 
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4,4,5,5-Tetramethyl-2-(2-methyl-1-phenylpropan-2-yl)-1,3,2-dioxaborolane (Table 3, Entry 
6; gram-scale reaction).  The title compound was prepared according to the General Procedure, 
using (2-bromo-2-methylpropyl)benzene (149 mg, 0.70 mmol).  The reaction was complete after 
2 h.  Solvent used for chromatography: hexanes/Et2O (40:1 → 30:1).  White solid. 
First run: 129 mg (71%).  Second run: 127 mg (70%). 
1H NMR (400 MHz; CDCl3): δ 7.23-7.17 (m, 4H), 7.15-7.11 (m, 1H), 2.60 (s, 2H), 1.19 (s, 12H), 
0.93 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 140.6, 130.4, 127.8, 125.8, 83.3, 46.6, 25.0 (6 CH3, confirmed by 
gHMQC). 
FT-IR (film) 3085, 3063, 3028, 2978, 2954, 2935, 2862, 1605, 1495, 1474, 1454, 1388, 1371, 1356, 
1309, 1274, 1214, 1166, 1135, 1110, 1032, 968, 908, 875, 851, 741, 703, 690, 669, 596, 579, 553, 486, 
457 cm-1. 
MS (EI) m/z (M+) calcd for C16H25BO2: 260, found: 260. 
The reaction was conducted on a gram-scale according to the General Procedure, using (2-
bromo-2-methylpropyl)benzene (1.49 g, 7.0 mmol).  The reaction was complete after 2 h.  
Solvent used for chromatography: hexanes/Et2O (40:1 → 30:1).  White solid (1.28 g, 70%). 
When the same reaction was conducted with half of the standard catalyst loading (5% 
NiBr2•diglyme, 6.6% ligand 1), the purified product was generated in 56% yield (1.03 g). 
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Ethyl 4-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pentanoate (Table 3, Entry 7).  
The title compound was prepared according to the General Procedure, using ethyl 4-bromo-4-
methylpentanoate (156 mg, 0.70 mmol).  The reaction was complete after 3 h.  Solvent used for 
chromatography: hexanes/Et2O (1:0 → 10:1).  Colorless liquid. 
First run: 99 mg (53%).  Second run: 98 mg (52%). 
1H NMR (400 MHz; CDCl3): δ 4.13 (q, J = 7.1 Hz, 2H), 2.32-2.28 (m, 2H), 1.65-1.61 (m, 2H), 
1.26 (t, J = 7.1 Hz, 3H), 1.24 (s, 12H), 0.95 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 174.3, 83.0, 60.1, 35.5, 31.4, 24.7, 24.5, 14.2. 
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FT-IR (film) 2979, 2939, 2864, 1737, 1477, 1391, 1372, 1311, 1246, 1168, 1137, 1029, 967, 853, 
777, 717, 692, 671, 580 cm-1. 
MS (EI) m/z (M+) calcd for C14H27BO4: 270, found: 255 (M+–CH3). 
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2-(6-Chloro-2-methylhexan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 3, Entry 8).  
The title compound was prepared according to the General Procedure, using 5-bromo-1-chloro-
5-methylhexane (150 mg, 0.70 mmol).  The reaction was complete after 2 h.  Solvent used for 
chromatography: hexanes/Et2O (1:0 → 40:1).  Colorless liquid. 
First run: 113 mg (62%).  Second run: 115 mg (63%). 
1H NMR (400 MHz; CDCl3): δ 3.50 (t, J = 6.8 Hz, 2H), 1.71 (pentet, J = 7.1 Hz, 2H), 1.39-1.30 
(m, 2H), 1.26-1.21 (m, 2H), 1.19 (s, 12H), 0.87 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 83.1, 45.4, 40.5, 33.7, 25.0, 24.9, 24.0. 
FT-IR (film) 2967, 2937, 2863, 1476, 1390, 1371, 1308, 1214, 1144, 1112, 1066, 967, 853, 741, 717, 
693, 670, 653, 580 cm-1. 
MS (EI) m/z (M+) calcd for C13H26BClO2: 260, found: 245 (M+–CH3). 
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2-(2,6-Dimethylhept-5-en-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (Table 3, Entry 9).  
The title compound was prepared according to the General Procedure, using 6-bromo-2,6-
dimethylhept-2-ene (144 mg, 0.70 mmol).  The reaction was complete after 2 h.  Solvent used for 
chromatography: hexanes/Et2O (1:0 → 40:1).  Colorless liquid. 
First run: 116 mg (66%).  Second run: 117 mg (66%). 
1H NMR (400 MHz; CDCl3): δ 5.12-5.06 (m, 1H), 1.92-1.86 (m, 2H), 1.64 (d, J = 1.1 Hz, 3H), 
1.57 (d, J = 0.7 Hz, 3H), 1.27-1.22 (m, 2H), 1.20 (s, 12H), 0.90 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 130.9, 125.6, 83.0, 41.5, 25.9, 25.4, 25.0, 24.9, 17.7. 
FT-IR (film) 2978, 2932, 2862, 1475, 1389, 1370, 1307, 1215, 1187, 1139, 967, 932, 856, 836, 743, 
717, 693, 671, 580 cm-1. 
MS (EI) m/z (M+) calcd for C15H29BO2: 252, found: 252. 
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V.  Nickel-Catalyzed Borylations (eq 2–4; Figures 1, 2, and 4) 
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4,4,6-Trimethyl-2-(4-phenylbutan-2-yl)-1,3,2-dioxaborinane (eq 2).  The title compound was 
prepared according to the General Procedure, using (3-bromobutyl)benzene (149 mg, 0.70 
mmol) and bis(hexylene glycolato)diboron instead of bis(pinacolato)diboron.  The reaction was 
complete after 12 h.  Solvent used for chromatography: hexanes/Et2O (40:1 → 20:1).  Colorless 
liquid. 
First run: 126 mg (69%).  Second run: 128 mg (70%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.22 (m, 2H), 7.18-7.11 (m, 3H), 4.16-4.07 (m, 1H), 2.63-2.50 
(m, 2H), 1.76-1.67 (m, 2H), 1.54-1.45 (m, 1H), 1.40-1.33 (m, 1H), 1.25-1.23 (m, 6H), 1.21 (d, J = 6.2 
Hz, 3H), 0.93 (d, J = 6.6 Hz, 3H), 0.91-0.84 (m, 1H). 
13C NMR (101 MHz; CDCl3): δ 143.9, 128.7, 128.3, 125.5, 70.4, 64.63, 64.62, 46.2, 35.93, 35.86, 
35.74, 35.67, 31.5, 28.31, 28.27, 23.5, 16.12, 16.04. 
FT-IR (film) 3085, 3062, 3026, 2973, 2931, 2868, 1604, 1496, 1455, 1415, 1390, 1344, 1303, 1273, 
1251, 1211, 1171, 1111, 1056, 1030, 896, 819, 769, 747, 699, 681 cm-1. 
MS (EI) m/z (M+) calcd for C16H25BO2: 260, found: 260. 
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4,4,5,5-Tetramethyl-2-(2-methyl-4-phenylbutan-2-yl)-1,3,2-dioxaborolane (eq 3).  The title 
compound was prepared according to the General Procedure, using (3-bromo-3-
methylbutyl)benzene (159 mg, 0.70 mmol).  The activated diboron reagent was added at –10 °C.  
The reaction was complete after 72 h at –10 °C.  Solvent used for chromatography: 
hexanes/Et2O (1:0 → 40:1).  White needles. 
First run: 153 mg (80%).  Second run: 155 mg (81%). 
1H NMR (400 MHz; CDCl3): δ 7.26-7.22 (m, 2H), 7.18-7.11 (m, 3H), 2.56-2.52 (m, 2H), 1.59-1.54 
(m, 2H), 1.24 (s, 12H), 0.98 (s, 6H). 
13C NMR (101 MHz; CDCl3): δ 143.9, 128.5, 128.4, 125.6, 83.2, 43.7, 33.3, 24.98, 24.97. 
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exo-2-(Bicyclo[2.2.1]heptan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [141091-39-
6]19a,25a,28 (eq 4).  The title compound was prepared according to the General Procedure, using 
exo-2-bromonorbornane (123 mg, 0.70 mmol).  The reaction was complete after 4 h.  Solvent 
used for chromatography: hexanes/Et2O (1:0 → 40:1).  Colorless liquid.  Diastereoselectivity: exo 
only. 
First run: 118 mg (76%).  Second run: 125 mg (81%). 
1H NMR (400 MHz; CDCl3): δ 2.25-2.23 (m, 1H), 2.20-2.16 (m, 1H), 1.53-1.40 (m, 3H), 1.34-1.28 
(m, 1H), 1.22-1.17 (m, 14H), 1.16-1.10 (m, 2H), 0.86-0.82 (m, 1H). 
13C NMR (101 MHz; CDCl3): δ 83.0, 38.9, 38.3, 36.8, 32.42, 32.38, 29.5, 24.9. 
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exo-2-(Bicyclo[2.2.1]heptan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane [141091-39-
6]19a,25a,28 (eq 4).  The title compound was prepared according to the General Procedure, using 
endo-2-bromonorbornane (123 mg, 0.70 mmol).  The reaction was complete after 4 h.  Solvent 
used for chromatography: hexanes/Et2O (1:0 → 40:1).  Colorless liquid.  Diastereoselectivity: exo 
only. 
First run: 120 mg (77%).  Second run: 118 mg (76%). 
1H NMR (400 MHz; CDCl3): δ 2.26-2.23 (m, 1H), 2.20-2.17 (m, 1H), 1.53-1.40 (m, 3H), 1.34-1.28 
(m, 1H), 1.24-1.17 (m, 14H), 1.16-1.10 (m, 2H), 0.86-0.82 (m, 1H). 
13C NMR (101 MHz; CDCl3): δ 83.0, 38.9, 38.3, 36.8, 32.42, 32.38, 29.5, 24.9. 
 
 
Procedure for Figures 1 and 4: KOEt (4.2 mg, 0.050 mmol, 0.25 equiv), pinB–Bpin (13.7 mg, 
0.054 mmol, 0.27 equiv), and i-Pr2O (1.0 mL) were added to a 4-mL vial in a nitrogen-filled 
glovebox.  The vial was sealed with a teflon-lined septum cap, and the mixture was stirred 
vigorously at r.t. for 1 h.  The following materials were added in turn to a second 4-mL vial: 
NiBr2•diglyme (3.5 mg, 0.010 mmol, 0.050 equiv), ligand 1 (4.0 mg, 0.013 mmol, 0.066 equiv), 
and DMA (290 µL).  The vial was sealed with a teflon-lined septum cap, and the mixture was 
stirred vigorously at r.t. for 1–2 h (or until the solution became almost or completely 
homogeneous).  Next, i-Pr2O (1.0 mL) and the pair of alkyl halides (0.20 mmol each; see Figures 
1 and 4) were added to this solution.  After stirring for 5 min, the white slurry of the activated 
diboron reagent was added within a 1-min period, followed by an i-Pr2O rinsing (0.3 mL).  The 
vial was sealed with a teflon-lined septum cap, and the mixture was stirred at r.t. for 1 h.  Next, 
n-dodecane (20.0 µL) was added to the vial as an internal standard, and the reaction mixture 
was analyzed by GC. 
                                                
(28) Pereira, S.; Srebnik, M. J. Am. Chem. Soc. 1996, 118, 909–910. 
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Procedure for Figure 2:9 Ni(cod)2 (2.8 mg, 0.010 mmol, 0.040 equiv), ligand 5 (6.6 mg, 0.020 
mmol, 0.080 equiv), and DMA (400 µL) were added to a 4-mL vial in a nitrogen-filled glovebox.  
The vial was sealed with a teflon-lined septum cap, and the mixture was stirred vigorously at 
r.t. for 20 min, resulting in a deep-blue solution.  The following materials were added in turn to 
a second 4-mL vial: the pair of alkyl bromides (0.25 mmol each; see Figure 2) and DMA (300 µL).  
The vial was sealed with a teflon-lined septum cap, and the mixture was stirred for 1 min.  Next, 
the solution of Ni(cod)2/ligand 5 in the first vial was treated with a solution of n-hexylzinc 
iodide (0.84 M in DMA; 80 µL, 0.068 mmol, 0.27 equiv).  The mixture was stirred for 1 min, and 
then the solution of alkyl bromides in DMA was added, followed by a DMA rinsing (100 µL).  
The vial was sealed with a teflon-lined septum cap, and the mixture was stirred at r.t. for 20 h.  
Next, the reaction was quenched with ethanol (0.50 mL), n-dodecane (25.0 µL) was added to the 
vial as an internal standard, and the reaction mixture was analyzed by GC. 
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4,4,5,5-Tetramethyl-2-(nonan-2-yl)-1,3,2-dioxaborolane (for Figure 4).  The title compound 
was prepared according to the General Procedure, using 2-bromononane (145 mg, 0.70 mmol).  
The reaction was complete after 3 h.  Solvent used for chromatography: hexanes/Et2O (1:0 → 
40:1).  Colorless oil (150 mg, 84%). 
1H NMR (400 MHz; CDCl3): δ 1.43-1.36 (m, 1H), 1.30-1.23 (m, 11H), 1.20 (s, 12H), 0.99-0.90 
(m, 4H), 0.84 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 82.9, 33.4, 32.1, 30.0, 29.5, 29.2, 24.94, 24.91, 22.9, 15.7, 14.3. 
FT-IR (film) 2978, 2957, 2925, 2855, 1465, 1406, 1387, 1315, 1274, 1244, 1215, 1146, 1112, 1007, 
968, 861, 688, 669, 579 cm-1. 
MS (EI) m/z (M+) calcd for C15H31BO2: 254, found: 254. 
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4,4,5,5-Tetramethyl-2-(undecan-2-yl)-1,3,2-dioxaborolane (for Figure 4).  The title 
compound was prepared according to the General Procedure, using 2-bromoundecane (165 mg, 
0.70 mmol).  The reaction was complete after 3 h.  Solvent used for chromatography: 
hexanes/Et2O (1:0 → 40:1).  Colorless oil (171 mg, 86%). 
1H NMR (400 MHz; CDCl3): δ 1.45-1.34 (m, 1H), 1.30-1.22 (m, 15H), 1.20 (s, 12H), 1.00-0.91 
(m, 4H), 0.84 (t, J = 6.9 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 82.9, 33.5, 32.1, 30.1, 29.85, 29.81, 29.5, 29.2, 24.94, 24.91, 22.9, 
15.7, 14.3. 
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FT-IR (film) 2978, 2957, 2925, 2854, 1466, 1406, 1387, 1371, 1315, 1270, 1215, 1146, 1111, 1006, 
968, 861, 688, 670, 579 cm-1. 
MS (EI) m/z (M+) calcd for C17H35BO2: 282, found: 282. 
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4,4,5,5-Tetramethyl-2-(tridecan-2-yl)-1,3,2-dioxaborolane (for Figure 4).  The title 
compound was prepared according to the General Procedure, using 2-iodotridecane (217 mg, 
0.70 mmol).  The reaction was complete after 3 h.  Solvent used for chromatography: 
hexanes/Et2O (1:0 → 40:1).  Colorless oil (184 mg, 84%). 
1H NMR (400 MHz; CDCl3): δ 1.43-1.36 (m, 1H), 1.30-1.22 (m, 19H), 1.20 (s, 12H), 0.99-0.90 
(m, 4H), 0.84 (t, J = 6.8 Hz, 3H). 
13C NMR (101 MHz; CDCl3): δ 82.9, 33.5, 32.1, 30.1, 29.88, 29.85, 29.84, 29.6, 29.2, 24.94, 24.91, 
22.9, 15.7, 14.3. 
FT-IR (film) 2925, 2854, 1466, 1406, 1386, 1315, 1272, 1216, 1146, 1111, 1006, 968, 861, 721, 688, 
671, 579, 522 cm-1. 
MS (EI) m/z (M+) calcd for C19H39BO2: 310, found: 310. 
 
 S–26 
VI.  1H NMR Spectra  
 
 S–27 
 
 S–28 
 
 S–29 
 
 S–30 
 
 S–31 
 
 
 S–32 
 
 S–33 
 
 S–34 
 
 S–35 
 
 S–36 
 
 S–37 
 
 S–38 
 
 S–39 
 
 S–40 
 
 S–41 
 
 S–42 
 
 
 S–43 
 
 
 S–44 
 
 S–45 
 
 S–46 
 
 S–47 
 
 
 S–48 
 
 S–49 
 
 S–50 
 
 S–51 
 
 S–52 
 
 S–53 
 
 
 S–54 
 
 
 S–55 
 
 S–56 
 
 S–57 
 
